- Home
- POM vs NRXS Comparison
POM vs NRXS Comparison
Compare POM & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POM | NRXS |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.2M | 46.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | POM | NRXS |
|---|---|---|
| Price | $0.33 | $7.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 194.3K |
| Earning Date | 05-03-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $146.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.19 | $1.33 |
| 52 Week High | $6.43 | $7.46 |
Technical Indicators
Market Signals| Indicator | POM | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 48.00 | 72.93 |
| Support Level | $0.28 | $2.38 |
| Resistance Level | $0.42 | N/A |
| Average True Range (ATR) | 0.06 | 0.57 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 45.53 | 85.71 |
Price Performance
Historical ComparisonAbout POM POMDOCTOR LIMITED American Depositary Shares
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).